What factors drove the changes in LENZ Therapeutics's revenue and profit?

What guidance did LENZ Therapeutics's management provide for the next earnings period?

What is the revenue and EPS growth rate for LENZ Therapeutics year over year?

What is the market's earnings forecast for LENZ Therapeutics next quarter?

What were the key takeaways from LENZ Therapeutics's earnings call?

What were the key takeaways from LENZ Therapeutics’s earnings call?

What is LENZ Therapeutics's gross profit margin?

What is LENZ Therapeutics's latest dividend and current dividend yield?

- **Category leadership solidified with 10,000+ ECPs and 45,000 boxes sold in Q1 2026.
- DTC campaign drives 5x website traffic growth.
- 2027 global expansion pipeline with 10+ potential approvals.


**【CEO Summary Section】**
- Product demonstrates strong real-world efficacy, with patients experiencing benefits within 30 minutes.
- Over 10,000 prescribing eye care professionals (ECPs) achieved within 5 months of launch.
- Cash balance of $292 million supports long-term category building.

**【CCO Commercial Strategy】**
- Direct-to-consumer (DTC) campaign drives 5x website traffic growth.
- Sales force expanded to 117 reps targeting 15,000 ECPs.
- 45,000 boxes sold through Q1 2026.

**【CFO Financial Update】
- Q4 2025 net product revenue $1.6 million; 2026 gross margin expected at 9%.
- 2027 international approvals anticipated in 10+ countries.

**【Q&A Highlights】**
- Refill rates align with internal expectations; 3-month prescriptions growing.
- DTC ads show 2x benchmark performance in click-through rates.
- Global expansion pipeline includes 5 NDAs submitted.


LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript

- **VIZZ Launch Success**: 2,500 prescribers and 5,000 scripts in first month, with positive ECP feedback on efficacy and transient side effects.
- **Financial Strength**: $324 million cash post-ATM, strategic partnerships yielding $12.5 million in Q3.
- **DTC Campaign**: SJP-led digital strategy set for Q1 2026, targeting 45-65 female presbyopes.
- **Financial Outlook**: 2026 SG&A spend projected at $80-100 million, supporting growth.

**【CEO Summary Section】**
- LENZ achieved a successful launch of VIZZ, with over 2,500 prescribers and 5,000 filled scripts in the first month. Doctors report high efficacy and minimal side effects, such as transient redness and stinging. The company announced a direct-to-consumer (DTC) campaign featuring Sarah Jessica Parker, targeting early 2026. Strategic partnerships include $12.5 million in license revenue from China and Canada deals.

**【CFO Financial Commentary】**
- Q3 2025 financials showed no product revenue, with $12.5 million in license revenue and a net loss of $16.7 million. Cash position strengthened to $324 million post-ATM placement, supporting the commercial launch. R&D expenses decreased by 58% sequentially, while SG&A increased 116% due to commercial ramp-up.

**【Q&A Key Highlights】**
- Early adoption metrics: 40% of prescribers wrote multiple scripts, and 90% of eye care professionals (ECPs) are aware of VIZZ. Sample conversion is strong, with 70,000 samples distributed. DTC campaign will focus on digital platforms, aligning with patient demographics (45-65, female, metropolitan). Financial preparedness for 2026 includes $80-100 million SG&A spend.

LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript

- **PDUFA-Ready Momentum**: Q1 2025 marked strong commercial prep for LNZ100, with 40% of sales force hired and FDA engagement unchanged.
- **Financial Strength**: $194.1M cash on hand, up 19% QoQ in SG&A spend for pre-launch activities.
- **Market Potential**: $3+ billion U.S. presbyopia market, targeting 8 million users with 95% clinical trial efficacy.
- **Tariff Resolution**: LNZ100 designated as U.S.-origin, ensuring duty-free status post-launch.

**【CEO Summary Section】**
- LENZ achieved significant progress in Q1 2025, with a strong focus on commercial readiness for the August 8, 2025 PDUFA date for LNZ100.
- The Commercial Day event demonstrated robust engagement from eye care professionals (ECPs), with over 12,000 ECPs reached and 2 million digital impressions.
- FDA interactions remain positive, with no personnel changes in the review team and a late-cycle meeting scheduled for late May.
- Tariff resolution confirmed LNZ100 as a U.S.-origin product, ensuring duty-free status.

**【CFO Financial Commentary】**
- Q1 2025 cash position: $194.1 million, up from $170 million previously guided, with $16.3 million net proceeds from a block trade.
- Operating expenses increased 11% QoQ to $16.9 million, driven by commercial headcount and pre-launch activities.
- SG&A expenses rose 19% QoQ to $11.3 million, reflecting sales force expansion and marketing spend.
- R&D expenses stabilized at $5.8 million, with focus on commercial product manufacturing.

**【CCO Commercial Strategy】**
- Sales force build-out: 40% of 88 field reps hired, with 97% prior eye care/pharma experience.
- Three-pillar strategy: ECP engagement (via MSL team and unbranded campaign), consumer awareness (brand launch in early 2026), and seamless access (5-day sample path, e-pharmacy partnerships).
- Sample distribution plan: rep-delivered to 15,000 ECPs, with 95% of clinical trial patients achieving near vision improvement within 1 hour.

**【Q&A Key Takeaways】**
- **Sampling Efficiency**: 5-day sample packs will be replenished monthly, with reps tracking script conversion rates.
- **Market Growth**: Targeting 8 million U.S. users, with potential $3+ billion market. Early metrics to watch: new scripts (IQVIA data), refill rates, and e-pharmacy adoption.
- **Economic Resilience**: Consumer discretionary spend on medical aesthetics (e.g., neurotoxins) shows minimal recession impact, with LNZ100 positioned as a quality-of-life enhancer.
- **IP Protection**: 7 granted patents (expiring 2039), 10 under review, and 5 years data exclusivity post-approval.


LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript

- **Regulatory Momentum**: On track for August 2025 FDA approval with no major issues flagged in mid-cycle review.
- **Manufacturing Readiness**: Commercial production underway, with packaging post-approval to ensure Q4 2025 launch.
- **Sales Force Strength**: 10 district managers and 2 regional directors hired, with 1,300+ applications for 88 territory reps.
- **Market Potential**: $3+ billion U.S. market with 128 million presbyopia sufferers; 82% of ECPs likely to prescribe LNZ100.
- **Financial Position**: $209 million cash runway as of Q4 2024, with disciplined spending to support launch.

**【Management Opening Remarks】**
- LENZ ended 2024 with $209 million in cash, providing a strong financial foundation for the 2025 launch of LNZ100.
- CFO Dan Chevallard highlighted the company's transition to a pre-commercial entity, emphasizing disciplined spending and preparation for the August 2025 PDUFA date.

**【CEO Commentary】**
- **Regulatory Progress**: Completed mid-cycle review with FDA, no significant issues noted; FDA inspections of clinical trial sites underway.
- **Manufacturing Milestone**: Initiated commercial product manufacturing in February, with inventory to be packaged post-approval.
- **Medical Affairs Momentum**: MSL team engaged over 1,000 ECPs in Q4, including a high-profile event at SECO 2025.
- **Intellectual Property Strength**: 7 granted U.S. patents with protection extending to 2044, plus 10 pending patents.
- **Sales Force Buildout**: Hired 10 district managers and 2 regional directors, with 88 territory reps recruitment underway (1,300+ applications received).

**【CCO Commentary】**
- **Market Opportunity**: 128 million presbyopia sufferers in the U.S., with $3+ billion potential market. LNZ100 Phase 3 data shows 90% of patients noticed vision improvement, 75% plan to use 4-7 days/week.
- **Commercial Strategy**: 
  1. **Doctor Engagement**: All-optometrist MSL team educating ECPs on pupil-selective mechanism and clinical data.
  2. **Consumer Demand**: Unbranded EYEAMSELECTIVE campaign targeting 30,000 ECPs, with 2 million digital impressions.
  3. **Access Enablement**: 5-day sample pack for seamless trial-to-purchase journey; e-pharmacy integration for home delivery.
- **Sales Force Quality**: 150+ years of eye care experience among leadership team; focus on hiring top talent for field reps.

**【CFO Financial Commentary】**
- Q4 2024: 
  - Total operating expenses: $15.2 million (down 40% YoY, up 18% QoQ due to commercial ramp).
  - Net loss: $12.7 million ($0.46 per share).
  - Cash burn: $8.1 million (consistent with prior quarter).
- **Expense Breakdown**: 
  - SG&A: $9.4 million (up 71% YoY, 44% QoQ) driven by sales force hiring and marketing.
  - R&D: $5.9 million (down 69% YoY, 9% QoQ) focused on manufacturing.
- **2025 Outlook**: Expect continued SG&A ramp as launch approaches, with G&A maintained at lean levels.

**【Q&A Highlights】**
- **Sales Force Targeting**: 15,000 high-prescribing ECPs (85% of Vuity scripts) vs. broader 40,000 optometrist universe.
- **Sampling Strategy**: 5-day sample pack designed for quick efficacy demonstration (95% of patients saw 2+ lines improvement on Day 1).
- **Competitive Differentiation**: Pupil-selective aceclidine mechanism vs. non-selective pilocarpine; 10-hour durability vs. 6-hour competitors.
- **Economic Sensitivity**: Presbyopia treatment viewed as discretionary but essential for quality of life; 82% of surveyed ECPs likely to prescribe LNZ100 post-approval.
- **Ex-U.S. Strategy**: China license in place (Phase 3 data pending); exploring partnerships for other markets.


LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript

- **Merger Completion**: $213M cash runway to support NDA submission and 2025 launch.
- **Phase 3 Success**: 71% of participants achieved 3+ lines of near vision improvement, with 95% showing clinically meaningful results.
- **Commercial Momentum**: KOL event in June to highlight subgroup data; third-party logistics contracted for 2025 launch.
- **Safety Profile**: No serious adverse events; mild, transient side effects with no retinal detachment risk.
- **Market Potential**: 68% of presbyopes would try the product, aligning with Phase 3 discontinuation survey.

**【CEO Summary Section】**
- Completed merger with Graphite Bio and $53.5M pipe financing, resulting in $213M cash runway to post-launch cash flow.
- Phase 3 CLARITY trial showed 71% of participants achieved 3+ lines of near vision improvement at 3 hours, with 95% achieving 2+ lines improvement.
- Planning NDA submission for LNZ100 in mid-2024, targeting FDA approval and commercial launch in H2 2025.
- Commercial readiness includes unbranded Eye Am campaign, KOL event on June 18, and third-party logistics contracting.

**【CFO Financial Commentary】**
- Q1 2024 cash balance: $213.3M (includes $117M from merger and $53.5M pipe financing).
- Total operating expenses: $16.1M (R&D: $10.5M, SG&A: $5.6M), up 28% YoY due to public company costs and pre-launch activities.
- Net loss: $16.6M, with 25.5M shares outstanding post-merger.
- 2024 capital allocation: reduce R&D spend post-NDA, increase commercial spend, and maintain G&A discipline.

**【Q&A Key Highlights】**
- **NDA Submission**: Team focused on compiling paperwork; confident in mid-2024 timeline. Stability studies aligned with filing schedule.
- **KOL Event (June 18)**: Will share subgroup analyses (e.g., age, LASIK status) and safety/tolerability data.
- **Adverse Events**: 0 serious AEs across 30,000 treatment days; 95% mild, transient AEs (e.g., headaches, stinging). No retinal detachment risk due to ciliary muscle-sparing mechanism.
- **Discontinuation Rate**: 25% of Phase 3 participants indicated they might not continue use, citing potential cost or satisfaction with current solutions. Market research suggests 68% presbyopes would try the product.

Actual	-24.15	-1.96	-2.45	-3.36	-3.36	-3.15	-3.08	-3.01	-6.79		-2.575	-3.53	-0.4	-0.38	-0.46	-0.53	-0.53	-0.59	-1.16
Forecast	-2.03	-1.9367	-2.0825	-2.73	-3.4394	-3.11	-3.4542	-2.408	-6.79	-1.75	-0.91	-0.82	-0.4787	-0.4582	-0.41	-0.5183	-0.6102	-0.6923	-0.9083
Surprise	-1089.66%	-1.20%	-17.65%	-23.08%	+2.31%	-1.29%	+10.83%	-25.00%	0.00%	0.00%	-182.97%	-330.49%	+16.44%	+17.07%	-12.20%	-2.26%	+13.14%	+14.78%	-27.71%

Actual	0	0	0	0	0	0	0	0	0	--	0	0	0	0	0	0	5.00M	12.50M	1.59M
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	714.29K	4.64M	3.08M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+600.00%	+169.23%	-48.50%

LENZ

LENZ fundamentals

LENZ Q4 2025 Earnings

Earnings Call

You can ask Aime

LENZ

LENZ fundamentals

LENZ Q4 2025 Earnings

Earnings Call

LENZ Earnings Call Summary for Q4/20258:30 AM on Mar 24, 2026

LENZ Earnings Call Summary for Q3/20258:30 AM on Nov 5, 2025

LENZ Earnings Call Summary for Q2/2025 Mar 25, 2026

LENZ Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

LENZ Earnings Call Summary for Q4/20244:30 PM on Mar 19, 2025

You can ask Aime